This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Sesen Bio Future Growth
Future criteria checks 0/6
Key information
19.3%
Earnings growth rate
4.4%
EPS growth rate
| Biotechs earnings growth | 20.7% |
| Revenue growth rate | -85.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 28 Feb 2023 |
Recent future growth updates
Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12Sesen Bio: Binary Event Approaching
Jun 13Sesen Bio inks global supply partnership with Qilu Pharmaceutical
Jun 02Sesen Bio EPS misses by $0.27
May 10Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
May 07News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Sesen announces positive FDA meeting for vicineum's marketing application
Feb 01Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio/Qilu Pharma's Vicineum IND application accepted for review in China
Jan 13Sesen Bio files US application for its Vicineum in bladder cancer
Dec 21Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Sesen Bio: A Look At Vicineum's Potential
Nov 29Sesen Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | N/A | -9 | -18 | N/A | 1 |
| 12/31/2024 | N/A | -8 | -8 | N/A | 1 |
| 12/31/2023 | N/A | -26 | -20 | N/A | 1 |
| 12/31/2022 | 40 | -20 | 25 | 25 | N/A |
| 9/30/2022 | 60 | -3 | 10 | 10 | N/A |
| 6/30/2022 | 20 | 48 | -29 | -29 | N/A |
| 3/31/2022 | 22 | 54 | -43 | -43 | N/A |
| 12/31/2021 | 27 | 0 | -69 | -69 | N/A |
| 9/30/2021 | 7 | -24 | -65 | -65 | N/A |
| 6/30/2021 | 18 | -118 | -54 | -54 | N/A |
| 3/31/2021 | 16 | -119 | -40 | -40 | N/A |
| 12/31/2020 | 11 | -23 | -31 | -31 | N/A |
| 9/30/2020 | 11 | -41 | -36 | -36 | N/A |
| 6/30/2020 | N/A | -32 | -39 | -39 | N/A |
| 3/31/2020 | N/A | -60 | -39 | -38 | N/A |
| 12/31/2019 | N/A | -107 | -38 | -38 | N/A |
| 9/30/2019 | N/A | -81 | -32 | -31 | N/A |
| 6/30/2019 | N/A | -82 | -30 | -30 | N/A |
| 3/31/2019 | N/A | -36 | -26 | -26 | N/A |
| 12/31/2018 | N/A | -34 | -23 | -23 | N/A |
| 9/30/2018 | N/A | -33 | -19 | -19 | N/A |
| 6/30/2018 | N/A | -29 | -18 | -18 | N/A |
| 3/31/2018 | N/A | -27 | -17 | -17 | N/A |
| 12/31/2017 | 0 | -29 | -18 | -18 | N/A |
| 9/30/2017 | 1 | -26 | -20 | -20 | N/A |
| 6/30/2017 | 30 | 3 | 6 | 6 | N/A |
| 3/31/2017 | 30 | 3 | 6 | 6 | N/A |
| 12/31/2016 | 30 | 2 | 3 | 3 | N/A |
| 9/30/2016 | 30 | -5 | N/A | -1 | N/A |
| 6/30/2016 | 1 | -34 | N/A | -31 | N/A |
| 3/31/2016 | 1 | -35 | N/A | -35 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SESN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SESN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SESN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SESN is forecast to have no revenue next year.
High Growth Revenue: SESN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SESN's Return on Equity is forecast to be high in 3 years time